Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.32 |
| ▸ | MC4R | P32245 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886261 | 0.88 | BRD4 (0.34) | KCNH2BRD4PDE1APDE1BPDE1C | |
| SCHEMBL5886442 | 0.87 | KCNH2 (0.36) | KCNH2BRD4 | |
| SCHEMBL4155476 | 0.86 | ALOX5AP (0.32) | KCNH2BRD4 | |
| SCHEMBL4163017 | 0.86 | KCNH2 (0.36) | MC4RKCNH2BRD4 | |
| SCHEMBL5886407 | 0.85 | KCNH2 (0.38) | APLNRKCNH2PIK3CAPIK3CG | |
| SCHEMBL5886360 | 0.85 | GRM5 (0.32) | KCNH2BRD4 | |
| SCHEMBL5886417 | 0.84 | KDM4E (0.34) | KCNH2BRD4 | |
| SCHEMBL5886393 | 0.84 | KCNH2 (0.33) | MC4RKCNH2BRD4TGFBR1 | |
| SCHEMBL5886401 | 0.84 | KCNH2 (0.32) | KCNH2BRD4 | |
| SCHEMBL5886344 | 0.83 | NPC1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122546-B2 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION (US) | 2006-10-17 | — | — | US | claimed |
| US-20040077653-A1 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION | 2004-04-22 | — | — | US | claimed |
| US-7122546-B2 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077653-A1 | Imidazol-1-ylmethyl pyridazine derivatives | GABRA5, GABRA1, GABRA2 | PDE10A 1740/4885MC4R 426/4885APLNR 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.